Gold Blue Gold soars on Nasdaq listing and newly announced expansion ambitions The company is developing one of Ghana's top gold assets and aims to buy up more mines Rowan DunneJuly 1, 2025
Medical and Pharmaceutical Citi boosts share target for ArriVent BioPharma by US$4 on positive trial data The biotech operator's lung cancer drug enabled 16-month progression-free survival among patients Rowan DunneJune 23, 2025
Cannabis SHF Holdings sees suspicious 87% spike on the back of partnership with FundCanna A peculiar number of accounts were recommending the stock on X Monday Rowan DunneApril 21, 2025
Psychedelics Psyence BioMed invests half a million into natural psychedelics operator PsyLabs In conjunction with the financing, Psyence has secured the option to receive a steady supply of ibogaine from PsyLabs Rowan DunneApril 16, 2025
Medical and Pharmaceutical 60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development The newly announced partnership sent shares up by 137% at the intraday peak on the Nasdaq Tuesday Rowan DunneApril 8, 2025
Psychedelics Intranasal delivery tech developer ‘Polyrizon’ plans to administer psychedelics The Israeli company has an unnamed new partner involved with unspecified psychedelic drugs Rowan DunneMarch 18, 2025
Beverages Quantum BioPharma soars on clinical trial success with ‘unbuzzd’ hangover cure supplement Shares are currently up by over 110% on the Nasdaq Rowan DunneFebruary 4, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025
Gold ‘It wasn’t our fault’: SSR Mining links Çöpler landslide to 3rd party engineering mistake A heap leach pad failure last February caused a catastrophic incident that killed 9 people Rowan DunneJanuary 16, 2025
Medical and Pharmaceutical SILO Pharma flies high on impending patent for intranasal PTSD drug The stock rose by 146% in early morning trading on the Nasdaq Rowan DunneJanuary 8, 2025